The efficacy of sacubatril valsartan after use varies from person to person due to individual differences and specific medical conditions. Sacubitril valsartan is indicated for adult patients with chronic heart failure with reduced ejection fraction, which reduces the risk of cardiovascular death and hospitalization for heart failure, as well as for patients with hypertension, especially those with combined heart failure, diabetes mellitus, and urinary protein. Adverse reactions such as angioedema, hypotension, renal impairment, and hyperkalemia may occur after use, and prompt discontinuation of the drug and medical attention are recommended. It is contraindicated in patients who are allergic to the product, patients with severe hepatic impairment, patients with biliary cirrhosis, patients with cholestasis, and patients with mid- and late-term pregnancy. In addition, patients who want to use Sacubitril Valsartan need to use this drug under the supervision of a doctor and not privately.